Ecker, Mark A. et al. used a label-free proteome workflow to examine ovarian cancer progression using 11 high-grade serous ovarian cancer (HGSC) patients’ cohort and identified nicotinamide N-methyltransferase NNMT as a key metabolic regulator of cancer-associated fibroblasts (CAF) phenotype differentiation and cancer progression, suggesting a potential therapeutic target [50]. This evidence concerns the gene NNMT and ovarian serous adenocarcinoma.